Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Laboratoire Aguettant, 1, rue Alexander Fleming, 69007 Lyon, France
Dzuveo 30 micrograms sublingual tablet.
| Pharmaceutical Form |
|---|
|
Sublingual tablet. Blue-coloured flat-faced tablet with round edges and a diameter of 3 mm. |
Each sublingual tablet contains 30 micrograms of sufentanil (as citrate).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Sufentanil is a synthetic, potent opioid with highly selective binding to μ-opioid receptors. Sufentanil acts as a full agonist in μ-opioid receptors. Sufentanil does not induce histamine release. |
| List of Excipients |
|---|
|
Mannitol E421 |
Dzuveo is packaged in a polypropylene single-dose applicator, which is packaged in a polyester film/LDPE/aluminium foil/LDPE sachet with an oxygen absorber.
Dzuveo will be available in cartons of 5 and 10. Not all pack sizes may be marketed.
Laboratoire Aguettant, 1, rue Alexander Fleming, 69007 Lyon, France
EU/1/18/1284/001
EU/1/18/1284/002
Date of first authorisation: 25 June 2018
Date of latest renewal: 24 March 2023
| Drug | Countries | |
|---|---|---|
| DZUVEO | Austria, Estonia, Croatia, Ireland, Lithuania, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.